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Abstract
Background
Cancer related cognitive impairments have been subjectively reported and objectively
detected in breast cancer patients treated with chemotherapy and are known to have a pro-
found negative impact on productivity, psychosocial well-being and overall quality of life.
Moderate levels of walking are known to be of benefit to the psychosocial well-being of
those affected by breast cancer and for managing cognitive impairment in healthy adults,
children, and the elderly. The purpose of this study is to investigate the effects of a home-
based, self-managed, moderate intensity walking intervention on subjective and objective
cognitive functioning in breast cancer patients undergoing chemotherapy.
Methods
A home-based, self-managed intervention that consisted of moderate levels of walking was
compared to usual care among breast cancer patients treated with chemotherapy in a ran-
domised controlled trial. Outcome measures included changes in subjective (CFQ) and
objectively detected cognitive functioning (Stroop, SART and two subscales from the WAIS-
Digit Span and Block Design). Fifty participants were randomised to either the intervention
group (n = 25), who completed 12 weeks of moderate intensity walking, or to the control
group (n = 25) mid-way through chemotherapy.
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Results
Compared with the control group, the self-managed walking intervention had positive effects
on perceived cognitive function but not on sustained attention, executive function, memory
or visual spatial skills when assessed objectively using neuropsychological measures.
Conclusion
This home-based, self-managed intervention is beneficial for protecting against perceived
cognitive decline in breast cancer patients treated with chemotherapy. There is a need for
further research to objectively assess cognitive decline within this population with larger
sample sizes of patients.
Trial registration
Current Controlled Trials ISRCTN50709297
Introduction
Cancer related cognitive impairments (CRCI) in breast cancer patients and survivors have
been subjectively reported [1] and objectively detected [2], [3] as an adverse reaction to che-
motherapy. Subjective cognitive function is defined as a patient’s self-perceived experience of
mental processes and function [4], whereas objective cognitive function refers to mental pro-
cesses that are assessed using neuropsychological measures [5]. Evidence suggests that 21–90%
of breast cancer patients report difficulties in cognitive function [1] and 15–45% are objectively
detected [6]. Chemotherapy can have long-term effects on self-reported and objective cogni-
tive functioning of breast cancer patients, with impairments evident from four months to 20
years post-chemotherapy [7], [8]. CRCI have been objectively detected and subjectively
reported in a range of cognitive domains including memory, attention, concentration and
executive function [5], [9], [10] and can be subtle or dramatic, temporary or permanent, and
stable or progressive [11]. Furthermore, cognitive decline as subjectively reported by cancer
survivors can have a profound negative impact on productivity and work ability [12], as well as
detrimental effects on patients’ feelings of fatigue, anxiety, depression and overall quality of life
[13], [14]. It has been suggested that subjective complaints and objective assessment of CRCI
are not associated with one another [15–18] but in fact associated with psychosocial distress
and fatigue [19] which may be a predisposing risk factor for developing CRCI following che-
motherapy for breast cancer [15–18], [20–24].
Despite growing evidence for subjective and objective CRCI, interventions addressing these
difficulties among breast cancer patients both during and following primary treatment for can-
cer have been limited, varied in methods, and report mixed results. The wide range of inter-
vention methods have included: cognitive behavioural training [25], [26]; cognitive training
[27–29]; memory training [30]; and physical activity programs ranging from Tai Chi, yoga and
Qigong (posture and breathing) to aerobic and resistance training and walking [31–38]. Mixed
effects on objective cognitive function have been found post-treatment in breast cancer survi-
vors, through the implementation of cognitive behavioural training [26], memory and health
training [30], cognitive training [27], [29] and physical activity [32], [33], [36], [38], [39]. Hart-
man et al. (2017) noted improvements in processing speed following a 12 week physical activ-
ity intervention in their sample of breast cancer survivors who were within 2 years of
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diagnosis, leading them to suggest the need for early implementation of exercise interventions.
Similarly, interventions to manage cognitive difficulties experienced by breast cancer patients
during chemotherapy have yielded mixed results [28], [31]. Poppelreuter et al. (2009) imple-
mented cognitive training strategies during chemotherapy and found no effects on objective
cognitive function, whereas Baumann et al. (2011) found positive effects on cognitive function
following 12 weeks of resistance training using a battery of neuropsychological measures.
In contrast, evidence demonstrates promising effects of easy-moderate levels of walking as
a protective strategy for managing cognitive impairment in healthy individuals, and the elderly
[40], [41] as assessed by objective measures. Greater physical activity has also been associated
with better working memory and executive function in breast cancer survivors [19], [42] as
detected objectively using neuropsychological measures. In light of the evidence outlined
above, we propose that moderate levels of walking may also be of benefit to patients receiving
chemotherapy for their breast cancer.
To our knowledge, this is the first intervention to investigate the effects of a self-managed,
home based, moderate intensity walking intervention among breast cancer patients receiving
chemotherapy.
The primary outcomes for the intervention were changes in subjective and objective cogni-
tive functioning. Secondary outcome measures investigated the effects of the intervention
upon the psychosocial functioning (anxiety, depression, fatigue, self-esteem and mood) of
breast cancer patients. The results for the secondary outcomes have been published elsewhere
[43].
In the current study we hypothesise that a self-managed, home based moderate intensity
walking intervention may help in managing CRCI experienced by breast cancer patients dur-
ing chemotherapy.
Method
Design
The randomised controlled parallel trial compared 12 weeks of self-managed moderate inten-
sity walking plus usual care (n = 25) to usual care alone (n = 25). Subjective and objective
assessments of cognitive functioning and psychosocial measures were completed pre-interven-
tion and 12 weeks later at post-intervention (the same measures were also completed prior to
the experimental sessions, but as this was only for the purpose of familiarisation, these data did
not contribute towards the main analyses). Ethical approval for the study was obtained from
both Loughborough University and the NHS Research Ethics Committee in East Midlands
and Northampton (REC ref: 11/EM/0437, date of REC approval: 02/02/12). All participants
provided written consent. Research was conducted according to the principles expressed in
the Declaration of Helsinki. At the time of initial participant enrolment, the researchers were
unaware of trial registration resulting in a delay in registering the current study. The authors
confirm that all ongoing and related trials for this intervention are registered.
Recruitment
Participants were recruited over a 16-month period from three outpatient clinics at the Leices-
ter Royal Infirmary, UK between 01/06/12 and 01/10/2013. Patients with a diagnosis of breast
cancer waiting to begin adjuvant or neo-adjuvant chemotherapy who were considered fit to
participate in moderate intensity exercise by their oncologist were invited to take part in the
study. The researcher met the participants following their initial consultations with their
oncologist, provided them with a participant information sheet and explained the nature of
the study. Those who showed an interest were followed up 5–7 days later. Women aged
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between 18 and 75 years were eligible for the study if they: had a primary diagnosis of stage I to
III breast cancer; were waiting to begin chemotherapy; were able to read and speak English;
were able to walk unassisted; and were relatively inactive (<30min a day, 5 times a week of
moderate intensity walking). They were excluded if they had previously been diagnosed with
cancer or if they had a current psychiatric illness that could hinder participation in the
intervention.
Procedure
Cognitive functioning was measured objectively using neuropsychological assessments and
subjectively using self-report measures of cognitive difficulties. Measures of Psychosocial well-
being and both objective and subjective measures of physical activity were also collected.
Experimental assessments took place at two-time points: pre-intervention (after two cycles of
chemotherapy) and post-intervention (after the completion of six cycles of chemotherapy). All
participants had been prescribed eight cycles of FEC or FEC-T chemotherapy. Participants
were randomised to either the intervention (n = 25) or control (n = 25) group after completing
the pre-intervention assessment. Following guidance from oncologists, the same measures
were also completed pre-chemotherapy to enable familiarisation with the researcher and
research methods (see Fig 1). Measures were counterbalanced within each of the cognitive
tasks to avoid practice effects.
Participants began the walking intervention after two cycles of treatment, as discussions
with oncologists suggested that the intervention would be better received after patients had
begun chemotherapy and understood what they were facing. Therefore, assessments of cogni-
tive and psychosocial functioning were compared at time two and time three (pre- and post-
intervention) in line with oncologist recommendations. Those who were randomised into the
physical activity group were provided with the intervention materials and those in the control
group continued with usual medical care alone provided by oncology nurses and doctors. At
the time of data collection, patients receiving treatment at the Leicester Royal Infirmary were
not routinely advised of the benefits of physical activity during chemotherapy and therefore
the control group did not receive any information from either the researcher or their medical
team encouraging them to be more active.
Intervention
The intervention consisted of 12 weeks of home-based, self-managed, moderate intensity
walking compared with usual care alone. The design of the walking intervention was based on
the Theory of Planned Behaviour (TPB) [44]. Full details of the intervention and materials are
reported elsewhere [43], [45]. Patients were provided with an intervention booklet including
guidance and recommendations to promote adherence to the intervention, tips and encour-
agement outlining the benefits of walking, and a copy of the Borg Rating of Perceived Exertion
Scale [46] (RPE) which encouraged them to rate the intensity of their walking. They were also
provided with a diary to keep a log of walking duration and intensity (using the RPE) and to
log their weekly goals based on principles of the TPB. Walking schedules were self-managed;
however, the researcher recommended that participants begin by completing 10 minutes of
walking at any one time and then steadily increasing the duration to 30 minutes five times a
week, in line with recommended guidelines of 150 minutes of moderate to vigorous intensity
exercise per week for the general population [47] and breast cancer survivors [48]. Patients
were also provided with the researcher’s contact details in case they had any questions regard-
ing the intervention or the booklet and were encouraged to discuss any potential side effects
with their health professionals should they occur.
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Fig 1. CONSORT Flowchart: Study recruitment and attrition rates.
https://doi.org/10.1371/journal.pone.0206874.g001
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The intervention group was provided with a Yamax Digi-Walker SW-200 pedometer for
the duration of the intervention to measure daily step count, to provide patients with immedi-
ate feedback, and with the aim of enhancing motivation for the 12-week period. They were
also asked to keep a daily exercise diary including the number of steps taken, duration of walk-
ing bouts and perceived exertion rates. Those randomised to the control group continued to
receive usual care alone.
Measures
Demographic information was gathered via a recruitment questionnaire and disease or treat-
ment related data was gathered via medical records. Assessments of psychosocial well-being
included anxiety and depression (Hospital Anxiety and Depression Scale) [49], mood (Profile
of Mood States) [50], fatigue (Functional Assessment of Cancer Therapy- Fatigue) [51], and
self-esteem (The Self-Esteem Scale) [52]. Further details about psychosocial measures can be
found elsewhere [43], [45]. Measures of cognitive functioning and physical activity are
described below. Self-reported physical activity and subjectively and objectively measured cog-
nitive function were conducted at familiarisation, pre and post intervention.
Objective measures of cognitive functioning
Executive function. A computerised version of the Stroop task [53] was used to measure
executive function in two blocks. The first required participants to name, using a key press, the
print colour of a series of four Xs, and the second consisted of colour words printed in incon-
gruent ink colours (e.g. the word ‘red’ printed in blue). The incongruent condition requires
inhibition of the pre-potent response of responding to word meaning. Reading the colour
name occurs as an automatic cognitive sub-routine, which interferes with the recognition of
the colour itself. In each of the two blocks, 96 stimuli were presented (24 presentations of four
colours: red, green, blue, and yellow) and in the incongruent task each colour word was pre-
sented six times in each of the four colours. The task was counterbalanced each time it was
completed (familiarisation, time two, and time three). Mean reaction time was recorded for
each of the two tasks, following the removal of outliers +/- 2 standard deviation’s (SD’s), and
an interference (difference) score was calculated to give a measure of executive functioning.
This task was chosen as it has frequently been used to illustrate CRCI in chemotherapy patients
[13], [23], [54], [55].
Working memory. Working memory was assessed using forwards and backwards digit
span as used in the Wechsler Adult Intelligence Scale-III [56]. Each task is made up of six pairs
of numbers which were read aloud by the researcher. The ‘digits forward’ version specifically
targets the phonological loop and requires participants to repeat number sequences in the
order in which they are presented. ‘Digits backwards’ targets the visuospatial sketchpad and
central executive processes of working memory by asking participants to repeat the number
sequence in reverse order, therefore making the task more challenging. Scoring was paper-
based with scores for digits forward ranging from 3–9 and digits backwards ranging from 2–8
with high scores in both tasks indicating better performance. Digit span is commonly used to
demonstrate CRCI in breast cancer patients [13], [23], [54], [55], [57], [58]. A meta-analysis of
the sensitivity of neuropsychological tests used to detect CRCI in breast cancer patients [59]
found that digit span produced the largest effect size out of all the tests they reviewed.
Attention. Sustained attention was measured using a computerised version of the Sus-
tained Attention to Response Task (SART) [60]. The task presented participants with
sequences of digits between 1 and 9 in a quasi-random order and varying font size at a rhyth-
mic rate of one every 250 milliseconds. There were 225 stimuli (each of the 9 digits displayed
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25 times), each followed by a mask displayed for 900 milliseconds. The mask is a ring with a
diagonal cross inside which acts as a distracter to break up the presentation of the digits. Par-
ticipants were asked to press the same response key each time, which rapidly becomes an auto-
matic response. However, they were required to withhold this automatic response when they
were presented with the number ‘3’. The number of false presses (responses to the number ‘3’)
and reaction times before and after false presses were recorded. The SART has previously dem-
onstrated lower scores of sustained attention in cancer patients who had higher levels of emo-
tional distress following diagnosis in comparison to patients who were more emotionally
stable at this same time point [61].
Perceptual organisation. Visuospatial skills were measured using the WAIS Block Design
as used in the Wechsler Adult Intelligence Scale-III [56]. This task required participants to
arrange a set of coloured blocks in the same pattern as that demonstrated by the researcher or
shown in picture format within the specified time limit. This becomes increasingly difficult
through the addition of blocks and the complexity of the designs presented. This test was
selected as in a previous meta-analysis [59] it demonstrated significant moderate effect sizes of
sensitivity in determining CRCI in breast cancer patients.
Self-reported cognitive functioning. The Cognitive Failures Questionnaire (CFQ) [62]
measured subjective cognitive functioning on a 25 item scale focusing on minor mistakes
made across a one month time frame. This self-report measure generates a score between 1
and 100, with higher scores indicating higher levels of subjective cognitive failures. The scale
takes approximately five minutes to complete and has frequently been used with breast cancer
patients [16], [21], [54], [63–65].
Physical activity
Accelerometer. All participants were provided with ActiGraph GT3X+ accelerometers
and were instructed to wear the device for 10 hours a day for seven days at baseline and after
the completion of chemotherapy. In line with previous findings, seven days of continuous
monitoring is recommended to assess habitual physical activity in adults and provides a trade-
off between feasibility, reliability and acceptable participant burden [66]. Accelerometers were
clipped to clothing or worn on a belt above the hip and measured the frequency, intensity and
duration of physical activity assessed through body movement.
Pedometer. The Yamax Digi-walker SW-200 pedometer was worn by participants rando-
mised to the intervention group for 10 hours a day for the duration of the 12-week interven-
tion. The devices were attached to participants’ clothing above the hip and recorded the
number of steps taken per day. Participants were asked to make a daily note of steps taken
before resetting the device.
Exertion. The Borg Rating of Perceived Exertion Scale [46] was completed by participants
in the intervention group to measure the intensity of walking exercises. Subjective measures of
perceived exertion are often measured using the RPE in this population [67–70]. The scale
asked participants to rate how hard they feel their bodies are working based on the physical
sensations they experience, including increased heart rate, breathing rate and sweating. Exer-
tion is measured on a rating scale between ‘6’ and ‘20’ with ‘6’ indicating ‘no exertion at all’
and ‘20’ indicating ‘maximal exertion’. Moderate intensity exercise is rated between 12 and 14
on Borg’s scale. Patients in the intervention group were asked to rate the exertion of their walk-
ing sessions and record it in their walking diaries. They were encouraged to aim towards walk-
ing at a moderate intensity.
The Talk Test [71] was used by participants within the intervention group as a guide to
monitor the intensity and pace of their walking. This informal subjective measure allows
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individuals to judge their own intensity with the understanding that if they are carrying out
moderate intensity walking they should still be able to maintain a conversation but not sing
(whereas carrying out vigorous intensity exercise will prevent individuals from speaking more
than a couple of words). The Talk Test was verbally explained to all participants in the inter-
vention group and it was also outlined in the booklets. Participants in the intervention group
were encouraged to use the measure whilst carrying out their walking exercises to gauge the
intensity of their walking and ensure that they were walking at moderate intensities. As this is
an informal measure for personal use by participants no data were recorded. However, it pro-
vided participants with immediate feedback regarding the intensity of their walking.
Levels of physical activity. The General Practice Physical Activity Questionnaire is a vali-
dated tool published by the Department of Health in 2002 to assess physical activity levels in
16–74 year olds. The questionnaire rates physical activity on four levels: active, moderately
active, moderately inactive, and inactive. The measure was used to gain subjective measures of
physical activity levels pre and post intervention.
Randomisation
Block randomisation using four blocks was used to allocate patients into one of two groups.
Within each group of four patients, two were allocated to the intervention group and two to
the control group, and the allocation of groups within each block was random. This method
was used rather than simple random allocation, to ensure equal numbers of consecutive
patients in both groups, as recruitment was staggered [72].
Sample size
Sample size calculations were based previous research with this population [25], [26]. The
study was designed to detect a standardised effect size of 0.5 [73] for repeated measures
ANOVA with a power of 0.80 and two-tailed α set at 5% significance level. Thus, 26 partici-
pants were needed per arm. To allow for attrition, 62 participants (31 in each arm) were
planned for recruitment. Over the recruitment period, a total of 63 participants completed
time one measures. However, 13 were lost due to attrition before randomisation and therefore
a total of 50 participants were split between the intervention and control arms.
Statistical analysis
All analyses were carried out using IBM SPSS version 21.0 for Windows. All between-group
differences in categorical variables were analysed using Pearson’s chi-square. Initial analyses
compared baseline ratings of subjective and objective outcomes of cognitive function.
Intention to treat (ITT) [74] analysis was used to include all randomised patients in the
groups to which they were randomly assigned regardless of subsequent withdrawal from treat-
ment or deviation from the protocol. Mixed model ANOVAs were used to test the difference
between the two groups (intervention and control) and difference within each group (pre and
post) on outcome measures of cognitive function. Scores at time one and time two were com-
pared for the control and intervention groups using t-tests to follow-up on significant interac-
tions. Lastly, Pearson’s correlations were conducted to explore the relationship between
variables of psychosocial well-being and self-reported cognitive function.
Results
Of the 96 eligible participants 33 (34%) declined participation due to high levels of distress fol-
lowing their diagnosis. In total, 63 breast cancer patients due to begin adjuvant and neo
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adjuvant chemotherapy met the inclusion criteria, consented to take part, and completed
recruitment measures (recruitment rate of 69%). A further 13 participants were lost to attri-
tion, due to changes in treatment as a result of chemotherapy related side effects, after provid-
ing consent. Therefore, 50 participants receiving chemotherapy were randomised to the
intervention (n = 25) or control group (n = 25) see Fig 1.
Sample characteristics
The age of participants in the intervention group ranged from 27–74 years (mean = 52.1 years;
SD = 11.7) and 29–66 years in the control group (mean = 52.4; SD = 8.9). The majority of par-
ticipants received adjuvant chemotherapy: 20 (80%) in the intervention group and 21 (84%) in
the control group (see Table 1).
Baseline characteristics
Chi-Square analysis revealed no significant differences in self-reported levels of physical activ-
ity between groups at pre-intervention x2 (2, N = 50) = 0.12, p = 0.94 (findings published else-
where [43]). Sixty four percent of the intervention group classed themselves as ‘inactive’
compared to 60% in the control group. There were no significant between group differences in
baseline measures using neuropsychological tests in the domains of sustained attention, execu-
tive function, memory and visuospatial skills. The intervention group had significantly lower
baseline scores on the measure of perceived cognitive function in comparison to the control
group; however, when within group effects was entered as a factor this difference was
accounted for within the analysis.
There was no significant difference in age between those who completed the study
(mean = 52 years; SD = 10.29) and those who withdrew (mean = 55 years; SD = 12.67) follow-
ing familiarisation. Those who withdrew from the study had lower educational qualifications
and were less likely to be in employment. Participants did not differ on any other demographic
or cancer-related characteristics (breast cancer type & grade, chemotherapy, treatment and
surgery type and menopausal status)- please refer to [43].
Adherence to the walking intervention
Adherence for the intervention group was calculated based upon the completion of the
12-week physical activity intervention, completion of intervention diaries, and goal setting.
Although adherence was not calculated based on total amount of physical activity completed
(as walking schedules were self-prescribed by individuals), the duration, intensity and fre-
quency of physical activity completed across the 12-week intervention is reported below.
Twenty (80%) out of the twenty-five participants who were randomised to the physical activity
group adhered to the intervention and completed walking diaries through recording of goal
setting, duration, intensity and frequency of their walking. Five participants discontinued par-
ticipation within the first few weeks of the 12-week intervention, did not complete diaries, but
completed all follow up measures post-intervention. Reasons for discontinuing participation
in the intervention included hospitalisation or medical complications.
Of the 20 participants that continued with the intervention, 16 completed walking diaries
on a weekly basis and four had one or more weeks of missing data due to hospitalisation but
continued with the intervention after they were discharged. Walking schedules were self-pre-
scribed, but it was recommended that participants should aim to walk for 30 minutes, five
times a week at moderate intensity. Analysis of weekly walking diaries revealed that the 20 par-
ticipants who completed the intervention walked at moderate intensity (as recorded using the
RPE) for an average of 157.4 minutes per week across the 12-week intervention. On average,
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patients participated in 4.85 walking sessions per week for an average of 30.49 minutes. Find-
ings suggest that the 20 participants who adhered to the intervention met the recommended
Table 1. Demographic and treatment characteristics for intervention and control group.
Characteristic Intervention (n = 25) Control (n = 25)
Age (years) M (SD) 52.08 (11.7) 52.36 (8.9) p = .500
BMI M (SD) 27.20 (4.82) 28.25 (5.83) p = .501
N % N % x2
Education
None 3 12 6 24
GCSE (or equivalent) 11 44 9 36
A level (or equivalent) 3 12 7 28 .279
Degree 5 20 2 8
Higher Degree 3 12 1 4
Marital status
Single 2 8 3 12
Married/living with partner 19 76 19 76
Separated/divorced 3 12 2 8
Widowed 1 4 1 4 .940
Employment status
Working 5 20 5 20
Sick leave 17 68 16 64
Retired 3 12 4 16 .917
Breast cancer type
Invasive ductal 24 96 23 92
Invasive lobular 1 4 2 8 .552
Cancer grade
I 0 0 1 4
II 5 20 8 32
III 20 80 16 64 .344
Chemotherapy type
FEC 12 48 9 36
FEC-T 13 52 16 64 .390
Treatment type
Adjuvant 20 80 21 84
Neo-adjuvant 5 20 4 16 .713
Surgery type
Lumpectomy 17 68 15 60
Mastectomy 7 28 10 40
Segmental 1 4 0 0 .437
Menopausal status
Pre-menopausal 12 48 7 28
Post-menopausal 13 52 18 72 .150
Self-report physical activity
Inactive 16 64 15 60
Moderately inactive 4 16 4 16
Moderately active 5 20 6 24
Active 0 0 0 0 .940
Note. FEC (fluorouracil, epirubicin and cyclophosphamide); FET-T (FEC followed by taxotere).
https://doi.org/10.1371/journal.pone.0206874.t001
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guidelines of 30 minutes of moderate intensity walking 5 times a week. There was no signifi-
cant difference between week one and week 12 of the intervention in the number of minutes
walked F (1, 19) = 0.14, p = 0.71 or the number of sessions completed F (1, 19) = 0.03, p = 0.85.
Findings indicate that patients were able to complete the recommended dose of physical activ-
ity throughout the course of the intervention and their chemotherapy treatment.
Findings revealed that participants walked an average of 36,217 steps per week as gathered
using the Yamax Digi-walker SW-200. There was no significant difference in the number of
steps recorded between week one and week 12 of the intervention F (1, 19) = 2.13, p = 0.16,
suggesting that levels of walking remained consistent across the 12-week period.
Effects of intervention on physical activity
Subjective. Chi-Square analysis showed that at post-intervention significant differences
were observed between groups on perceived levels of physical activity, x2 (3, N = 50) = 17.15,
p = 0.001. When looking at groups separately, the majority of the intervention group (36%)
classed themselves as ‘active’ compared with 0% in the control group (please refer to table of
result published elsewhere [45]. Those who received the physical activity intervention altered
their levels of perceived physical activity from ‘inactive’ to ‘active’. Furthermore, the majority
of the control group remained in the inactive group across the 12-week period. Findings indi-
cate a positive change in subjective levels of physical activity following the 12-week
intervention.
Objective. Comparisons between objective measures of physical activity between groups
were not possible due to low compliance of wearing and returning accelerometers. Thirty-one
participants (49%) out of the 63 who completed the familiarisation session at baseline (pre-
chemotherapy), returned accelerometers. A total of 32 patients were lost due to non-compli-
ance. The most common reasons for missing data were forgetting to wear the device and for-
getting to return the device to the researcher. Out of the 31 participants who returned data, six
participants complied with recommended wear time with an average of five days, and average
wear per day ranged from 39 minutes to 7 hours. Wear time for the 25 participants that did
not comply ranged from 7 hours to 3 days.
Participants were asked to wear the device for a further 7 days post-intervention, after the
completion of their chemotherapy. Of the 50 participants randomised, seven participants in
the intervention arm and three in the control group returned accelerometers at post-interven-
tion. The most common reasons for missing data at post-intervention were forgetting to wear
the device, wearing the device incorrectly preventing valid data collection, declining to wear
the device, or not returning the device. Due to low numbers and non-compliance, wear time
analysis between groups across the intervention period were not possible. At post-interven-
tion, Chi-square analyses showed no significant differences between the intervention and con-
trol group in the proportion of patients forgetting to wear the accelerometer, wearing the
device incorrectly preventing valid data collection, declining to wear the device, or not return-
ing the device, x2 (3, N = 40) = 2.41, p = 0.49.
Effect of physical activity intervention on cognitive functioning
Analysis of objectively measured cognitive performance revealed no significant main effects
for between or within group, or a significant interaction between the two for Stroop interfer-
ence, sustained attention, visuospatial skills, or memory as assessed by the digit backwards
task. There was also no significant interaction for the digit span forwards task. Additional anal-
yses were conducted to examine the main effects whilst removing the interaction as this can
mask a significant main effect. There were small effect sizes for the non-significant interactions
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effects for all measures of objective cognitive functioning. Therefore, these non-significant
findings could be due to an inadequate sample size. However, there were significant main
effects between groups F (1, 48) = 8.27, p< 0.01, ƞp2 = 0.147 and within groups, F (1, 48) =
4.55, p = 0.03, ƞp2 = 0.087. Inspection of the means indicated that digit span was slightly,
though significantly, greater in the intervention group (mean = 7.8, SD = 1.21) than the control
group (mean = 6.8, SD = 1.09) and at post-intervention (mean = 7.4, SD = 1.24) compared
with pre-intervention (mean = 7.0, SD = 1.18).
Analysis of self-reported cognitive failures revealed a significant interaction, F (1, 48) =
3.90; p = 0.05, ƞp2 = 0.075. As seen in Table 2, although scores remained stable in the interven-
tion group across the 12 week period, t (24) = -1.26, p = 0.9, they increased significantly in the
Table 2. Mixed model ANOVAs to test the difference between the two groups (intervention and control) and difference within each group (pre and post) on out-
come measures of cognitive function.
Variable Pre-intervention Post-intervention
Intervention (n = 25) Control (n = 25) Intervention (n = 25) Control (n = 25)
Perceived cognitive functioning
CFQ
32.48 (7.05) 39.20 (10.12) 32.68 (8.36) 45.44 (17.35) Test of Time x Group Interaction
F = 3.90
p = 0.05
ƞp2 = 0.075
Test of Main Effects
Between-participant effects Within-participant effects
(Group) (Time)
Sustained attention
Errors of omission 7.60 (4.53) 8.96 (4.43) 6.56 (3.35) 9.08 (4.41) F = 3.18 F = 0.88
p = 0.81 p = 0.35
ƞp2 = 0.062 ƞp2 = 0.018
Correct 396.95 (55.25) 378.62 (89.99) 407.59 (35.02) 386.22 (97.92) F = 1.01 F = 1.57
p = 0.31 p = 0.21
ƞp2 = 0.021 ƞp2 = 0.032
Incorrect 364.65 (54.21) 352.32 (83.83) 357.69 (80.38) 353.47 (68.22) F = 0.21 F = 0.08
p = 0.64 p = 0.76
ƞp2 = 0.004 ƞp2 = 0.002
Executive Function
Stroop Interference 145.87 (203.85) 219.18 (190.20) 118.93 (125.98) 177.08 (172.71) F = 2.17 F = 2.78
p = 0.15 p = 0.10
ƞp2 = 0.042 ƞp2 = 0.055
Memory
Digit forwards 7.32 (1.37) 6.68 (0.85) 7.84 (1.21) 6.81 (1.09) F = 8.27 F = 4.58
p<0.001�� p = 0.03�
ƞp2 = 0.147 ƞp2 = 0.087
Digit backwards 5.56 (1.32) 5.13 (1.54) 5.21 (1.71) 4.88 (1.45) F = 1.03 F = 1.91
p = 0.84 p = 0.173
ƞp2 = 0.022 ƞp2 = 0.040
Visual Spatial Skills
Block Design 36.58 (10.77) 35.52 (18.75) 34.83 (12.38) 36.26 (8.67) F = 0.00 F = 0.76
p = 0.95 p = 0.78
ƞp2<0.01 ƞp2 = 0.002
M, Mean, SD, standard deviation
�p<0.05
��p<0.01.
ͣWelch’s F (assumption of homogeneity of variance violated).
https://doi.org/10.1371/journal.pone.0206874.t002
Walking and cognitive function among breast cancer patients undergoing chemotherapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0206874 November 28, 2018 12 / 23
control group, t (24) = -2.39, p = 0.02, suggesting that the walking intervention protected
against self-reported cognitive decline. Inspection of the means indicated that self-reported
cognitive failures were significantly higher in the control group (mean = 45.4, SD = 17.3) than
the intervention group (mean = 32.7, SD = 8.4) post-intervention.
Exploratory analysis between self-reported cognitive function, psychosocial
well-being and physical activity
Further exploratory analysis was conducted in order to examine if any psychosocial wellbeing
variables contributed towards self-reported cognitive failures. Change scores from pre- to
post-intervention were calculated, and correlations conducted for each group between change
in reported cognitive failures and change in depression, anxiety, self-esteem, fatigue, and
mood; however no significant associations were observed. Similarly, correlations conducted
for each group between change in reported cognitive function and objectively detected cogni-
tive function were non-significant.
Exploratory analyses were conducted using Pearson’s two-tailed correlations to explore the
relationship between the amount of self-reported physical activity completed by the interven-
tion group and subjective cognitive function. These revealed a significant negative correlation
between mean duration of walking (in minutes) and self-reported cognitive failures, rs = -0.40,
p = 0.05, suggesting that as physical activity increased, self-reported cognitive failures
decreased.
Discussion
This randomised controlled trial is the first to investigate moderate levels of a self-managed,
home-based walking intervention on cognitive functioning of patients during chemotherapy
treatment for their breast cancer. The aim of the study was to assess the effectiveness of a self-
managed, home-based walking intervention on subjectively reported and objectively assessed
cognitive function during chemotherapy. There was no effect of the intervention on neuropsy-
chological measures of cognitive function. However, small effect sizes for all non-significant
interactions for objective measures of cognitive function suggest that these could be explained
by the small sample size. We found that perceived cognitive impairment (as measured by self-
reported cognitive failures) remained stable in the intervention group whereas it declined in
the control group, indicating that moderate levels of walking may help to protect against
decline in self-reported cognitive functioning. The maintenance of subjectively perceived cog-
nitive function in the intervention group provides further support for previous literature
reporting the benefits of physical activity such as Tai Chi [39] and Qigong [36] in breast cancer
patients on improving self-reported cognitive function. Patients are aware of perceived cogni-
tive impairments and the negative impact they can place on overall quality of life, therefore the
maintenance of perceived cognitive functioning is noteworthy as it has important implications
for the overall health of patients during treatment.
Exploratory correlations between change in reported cognitive failures and change in
depression, anxiety, self-esteem, fatigue, and mood were non-significant. Contrary to predic-
tions, maintenance of perceived cognitive function was not due to improvements in psychoso-
cial well-being following the completion of the home-based moderate intensity walking
intervention but may be due to a direct effect of participating in the self-managed walking
intervention.
Furthermore, duration of walking completed by patients was negatively associated with
self-reported cognitive function, suggesting that as physical activity increased, self-reported
cognitive failures decreased, and that improvements in subjectively detected cognitive function
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might be dose-dependent. The dose-dependent relationship between duration of physical
activity and perceived cognitive function make vital contributions to limited literature within
this area of research, leading to crucial implications for the healthcare of breast cancer patients
treated with chemotherapy.
As previously reported [43], breast cancer patients completing 12 weeks of moderate inten-
sity walking had better psychosocial functioning in comparison to usual care alone. Therefore,
this suggests that improvements in psychosocial well-being are not a direct reflection of the
amount of physical activity completed but rather the result of patients participating in physical
activity. Findings from our study do not support previous findings which suggest a direct rela-
tionship between the amount of physical activity completed and psychosocial well-being in
breast cancer survivors treated with chemotherapy [75]. Inconsistencies between our study
and previous findings may be explained by the self-prescribed nature of our study. Our find-
ings suggest that rather than imposing pressure to conform to a prescribed dose of exercise,
successful outcomes may be achieved with self-prescribed levels of physical activity. This
notion is further supported by a study investigating the effects of prescribed doses of exercise
in depressed patients [76] which reported that completing preferred levels of physical activity
produced better psychological and social outcomes in comparison to those completing inter-
ventions with prescribed doses of exercise.
To the authors’ knowledge, this is the first intervention to investigate the effects of a self-
managed, home-based, walking intervention during chemotherapy for breast cancer and
makes vital contributions to current evidence and clinical practice. This self-managed inter-
vention requires very little input from health professionals and therefore has the potential to
mitigate impairments in perceived cognitive function for a large number of breast cancer
patients’ receiving chemotherapy. However, as it is the first intervention of its kind and has a
relatively small sample size, as highlighted by small effect sizes for all non-significant measures
of objective cognitive function, further research with larger sample size is required to confirm
findings. Future interventions could examine the dose and intensity of physical activity
required for effective maintenance of self-reported cognitive function.
Contrary to previous research, there was no effect of the intervention on neuropsychologi-
cal measures assessing sustained attention, executive function, memory and visuospatial skills.
However, as the effect sizes for non-significant interactions were small, this suggests that fur-
ther research with larger sample sizes would help to clarify these findings. Moderate levels of
exercise have demonstrated positive effects on cognitive function among breast cancer patients
[31], [42], healthy adults, and the elderly [41], [77]. In line with the current study, 20 minute
bouts of moderate intensity walking have previously been found to reduce the risk of develop-
ing Alzheimer’s disease in adults [41]. Moderate to vigorous amounts of physical activity
among breast cancer survivors has also been associated with better executive function and
working memory [19], [42]. Therefore, findings from the current study were unexpected, as it
was anticipated that similar benefits would be seen among our sample of breast cancer
patients.
A possible explanation for null findings of objective cognitive function in the current study
may be the intensity and dose of physical activity completed in our small sample of patients.
As discussed above, evidence suggest that moderate levels of physical activity can help to
improve cognitive functioning [19], [31], [41], [42]. However, unfortunately, due to the lack of
valid data collected through accelerometers as an objective measure of physical activity, in the
current study we are unable to objectively determine if patients were completing the intensity
of physical activity required to observe improvements in neuropsychological measures of cog-
nitive function. Furthermore, although the self-perception of activity levels changed from
‘inactive’ to ‘active’ in the intervention group following 12 weeks of walking, data collected
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through diaries suggested that overall there was no increase in physical activity over the
12-week period. Therefore, it is possible that the amount and levels of physical activity com-
pleted by our sample were not effective in eliciting changes in objective cognitive function and
is a limitation of the current study.
A further possible explanation for not detecting an effect of the intervention on objectively
measured cognitive function may be due to the selection of neuropsychological measures and
the subtle nature of cognitive difficulties experienced by breast cancer patients. Evidence sug-
gests that many standard neuropsychological tests do not detect subtle change experienced by
cancer patients [9]. The neuropsychological measures included in the study were selected as in
previous research they have successfully detected chemotherapy-induced cognitive decline in
breast cancer patients. However, it may be that the selected tests are not sensitive enough to
pick up on subtle differences experienced by patients across the 12-week intervention period.
A review by the International Cognition and Cancer Task Force [78] has proposed the use of
the Hopkins Verbal Learning Test-Revised, Trail Making Test and the Controlled Oral Word
Association [79]. Unfortunately, the recommendation to use these tests was not published at
the time of designing the current study but may be a valuable addition for future studies to
detect subtle cognitive deficits experienced by breast cancer patients during chemotherapy.
In the present study there were no significant effects relating to the backwards digit span
task, whilst there was a small but significant improvement in recall on the forwards task from
pre- to post-intervention, and superior performance overall for the intervention group com-
pared with the control. It is unclear why our findings differed for the forwards and backwards
tasks. However, there is evidence that different strategies are employed during forwards and
backwards recall. One argument suggests that, unlike forwards recall, backwards recall
involves executive control and may be considered as a complex span measure of working
memory [80]. Similarly, the improvements in the forwards task could be explained by the sim-
ple recall of digits forwards as opposed to the complex nature of recalling digits backwards
which require the use of executive function and attention. Therefore, this is consistent with the
null findings observed in the other complex measures of cognitive functioning used in the
present study. Mixed measures analyses comparing objective levels of physical activity between
groups at pre- and post-intervention were not possible due to low compliance of wearing and
returning accelerometers. This is a limitation of the current study but provides vital contribu-
tions to research within this vulnerable population. It is anticipated that low compliance was
largely the result of the timing in which participants were asked to wear the device. Baseline
data was collected in the period between initial consultations with oncologists informing par-
ticipants that they would receive chemotherapy and beginning treatment. This is a highly dis-
tressing time for patients when many are still coming to terms with their diagnosis and are
preparing for chemotherapy both physically and emotionally. Follow up measures of objective
levels of physical activity were gathered post-intervention when patients had completed treat-
ment and were no longer visiting the hospital.
Previous home-based studies have successfully measured objective levels of physical activity
using pedometers or accelerometers, [81–83] and therefore our lack of valid data is surprising.
However, these studies were conducted with cancer survivors post-treatment. For breast can-
cer patients facing treatments other validated measures worn on the wrist or thigh, which were
not available at the time of this study, may provide more convenient and accurate collection of
objective physical activity. Furthermore, direct interaction with health care professionals in
previous studies may have acted as motivation to wear the device for the recommended 7 days.
Future self-managed, home-based studies assessing objective levels of physical activity during
treatment should consider daily notifications reminding participants to wear their device.
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The 80% adherence rate to the intervention is noteworthy and a strength of the self-man-
aged, home-based intervention in line with previous evidence which reported that over 50% of
breast cancer patients prefer to exercise alone [84]. Current findings suggest that the interven-
tion was well-received by breast cancer patients receiving chemotherapy and emphasises the
need for more self-managed interventions within this population. Further self-managed inter-
vention studies with larger sample sizes of patients receiving treatment for their breast cancer
are required in order to strengthen current findings that moderate levels of physical activity
can protect patients from a decline in subjective cognitive function.
Overall, our study reports benefits of a self-managed, home-based, moderate intensity walk-
ing intervention upon cognitive function when subjectively reported but not objectively
detected. These findings further support existing evidence for the lack of associations between
subjective and objective measures of cognitive decline experienced by breast cancer patients
[1]. A possible explanation for the discrepancy in the reporting and measuring of cognitive
decline in our study could be due to differences in methodological procedures involved in the
gathering of data. Objective measures of cognitive function only provide a snapshot of the
individual’s levels of functioning at the time of assessment and may not detect decline. On the
other hand, self-report measures ask patients to rate their experiences over a period of time,
which may result in more accurate levels of reporting. Discrepancies between the reporting
and measurement of cognitive decline in our sample further support previous studies [1] and
confirms the need to include both objective and subjective measures of assessment to provide
a comprehensive understanding of patients’ cognitive function.
Positive findings using self-report measures are noteworthy, as patients are concerned with
perceived deficits and the impact it places on their quality of life. Therefore, maintaining self-
reported cognitive function is important to patients, even though perceived deficits have a lim-
ited association with objective measures. This study makes a vital contribution towards the
advancement of current clinical practice to improve the quality of life of patients during treat-
ment. Furthermore, the self-managed, home-based nature of the study requires little input
from healthcare professionals and therefore can be implemented to benefit a larger population
of patients.
Conclusion
The self-managed, home-based intervention had a good adherence rate and was successful in
protecting against decline in self-reported cognitive difficulties experienced by patients treated
with chemotherapy for their breast cancer. Surprisingly, intervention effects were not detected
for objective measures of sustained attention, executive function, memory and visual spatial
skills in the current study, which could be explained by our small effect sizes. Therefore, fur-
ther investigations with large sample sizes conducted over multiple sites are required in order
to examine the effects of physical activity upon objectively detected cognitive impairment
among breast cancer patients. These studies should optimise the use of the standardised set of
neuropsychological measures recently acknowledged as suitable for detecting subtle cognitive
decline experienced by breast cancer patients [78] and should also provide daily notification
reminders to patients to wear their accelerometers in order to optimise the collection of objec-
tive measures of physical activity.
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